Dynavax Technologies Corporation
NASDAQ: DVAX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ryan Spencer
- Employees
- 405
- Headquarters
- EmeryVille, United States
- IPO year
- 2004
- Market cap
- $1.8B
- Website
- https://www.dynavax.com
Loading DVAX…
Loading profile data…Frequently asked questions about DVAX
What does Dynavax Technologies Corporation (DVAX) do?
Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified su...
Where does DVAX trade?
Dynavax Technologies Corporation (DVAX) trades on the NASDAQ Capital Market.
What sector is DVAX in?
Dynavax Technologies Corporation (DVAX) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Dynavax Technologies Corporation?
Ryan Spencer is the chief executive officer of Dynavax Technologies Corporation (DVAX).
Where is Dynavax Technologies Corporation headquartered?
Dynavax Technologies Corporation is headquartered in United States.
Does DVAX pay a dividend?
Dynavax Technologies Corporation (DVAX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DVAX go public?
Dynavax Technologies Corporation (DVAX) completed its initial public offering in 2004.